Floatz Rating
CCC54/100
Confidence
Indicative
Sponsor
Grupo Espanol de Tumores Neuroendocrinos
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02402062CT.gov A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neuroendocrine Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Evofosfamide (this asset) | Grupo Espanol de Tumores Neuroendocrinos | P2 | CCC · 54 |
| Fluorouracilum | ITM Solucin GmbH | P3 | BB |
| Irinotecan | First Affiliated Hospital Xi'an Jiaotong University | P4 | BB |
| Cabozantinib | Fox Chase Cancer Center | P3 | BB |
| Surufatinib | Shanghai Changzheng Hospital | P3 | BB |
| Everolimus | Exelixis | P3 | BB |
| Oxodotreotide | Fundación de investigación HM | P3 | BB |
| Carboplatin | First Affiliated Hospital Xi'an Jiaotong University | P4 | B |
| L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))- | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | P4 | B |
+42 more in the Neuroendocrine Neoplasm cohort
Other indications for Evofosfamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Pancreatic Adenocarcinoma | — | P3 | B · 63 |
| Pancreatic Neoplasm | — | P2 | B · 56 |
| Head And Neck Squamous Cell Carcinoma | — | P1/2 | CCC · 54 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Evofosfamide in Neuroendocrine Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/evofosfamide-neuroendocrine-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →